Teleflex’s Integration Delays and Freesolve Trial Timelines Don’t Match in Q2 2026 Earnings Call

Date of Call: Aug 6, 2026

Financials Results

• Revenue: $570.3 million, up 28.9% YOY on a GAAP basis and up 4.7% on a pro forma adjusted constant currency basis
• EPS: $1.76 per diluted share, a 1.7% increase YOY
• Gross Margin: 61.7%, a 280 basis point decrease YOY
• Operating Margin: 19.6%, a 520 basis point decrease YOY

Guidance:

• Pro forma adjusted constant currency revenue growth for 2026 expected in a range of 3.5% to 4.5% (previously 4.5% to 5.5%).
• Adjusted EPS for 2026 expected in a range of $6.90 to $7.20 (previously $6.25 to $6.55).
• Adjusted operating margin for 2026 expected to be approximately 19%.
• Net interest expense for 2026 expected to be approximately $85 million (previously ~$105 million).
• Adjusted tax rate for 2026 expected to be approximately 12.25% (previously ~13.5%).
• Expects meaningful step up in financial performance in 2027 and beyond, with significant increases in adjusted operating margin and adjusted EPS.

Business Commentary:

Revenue Growth and Margin Performance:

• Teleflex reported revenue of $570.3 million for Q2 2026, up 28.9% year-over-year on a gap basis and 4.7% on a pro forma adjusted constant currency basis.
• The growth was driven by strong execution in the vascular and surgical businesses, although interventional performance fell short of expectations due to integration challenges from the VI acquisition.

Divestitures and Capital Allocation:

• The company successfully closed the OEM divestiture, generating estimated after-tax proceeds of $1.25 billion, which will fund debt reduction and share repurchase.
• The strategic divestiture aims to create a more focused portfolio for high acuity hospital markets and strengthen Teleflex's financial portfolio.

Strategic Focus and Integration Challenges:

• The new CEO emphasized the importance of strategic and operational assessment to drive sustainable growth, innovation, and operational leverage.
• Integration issues in the interventional business were attributed to order-to-cash transitions, distributor transitions, and sales force realignment, which are considered transient but required mitigation efforts.

R&D Investment and Innovation:

• Teleflex increased its R&D investment to 7.9% of sales in the first half of 2026, focusing on new product opportunities that fortify the existing product portfolio.
• Key innovation developments include the FDA approval for EasyPlaz freeze-dried plasma and clinical trial milestones for Freezall, highlighting the company's focus on future growth opportunities.

Financial Guidance and Outlook:

• The company updated its 2026 guidance, reducing pro forma adjusted constant currency revenue growth to 3.5% to 4.5% due to the extended timeline for interventional integration.
• Despite the integration challenges, Teleflex anticipates meaningful improvements in adjusted operating margin and adjusted EPS, expecting a significant step up in financial performance in 2027 and beyond.

Sentiment Analysis:

Overall Tone: Positive

• Management expressed confidence in the long-term strategic and financial prospects, highlighting 'excellent performance' in vascular and surgical, 'significant progress' on the strategic transition, and new product innovations like EasyPlaz and FreeZolve. The CEO stated, 'I remain confident in that we're on the right path.' They expect 'meaningful increases' in profitability and EPS going forward.

Q&A:

• Question from Jason Bedford (Raymond James and Associates): Are there any pieces of the strategy that make you uncomfortable? Can you point out any areas of opportunity that maybe were not clear when you stepped into the role?
  Response: Confident in the transformational strategy and direction; currently conducting a comprehensive assessment to develop a long-term plan for durable growth and shareholder value.

• Question from Jason Bedford (Raymond James and Associates): Can you elaborate a bit more on the VI integration issue and what needs to happen to fully integrate the business?
  Response: Integration delays are due to transient order-to-cash, distributor, and Salesforce transitions, not product issues. Mitigations are in place, and confidence is high that issues will be worked through by year-end.

• Question from Vik Chopra (BMO Capital Markets): How quickly do you expect to communicate the outcome of your strategic review? Should we invest?
  Response: A formal long-range plan will be shared by the next earnings call; more color will be provided then.

• Question from Vik Chopra (BMO Capital Markets): What level of confidence do you have that the current timeline reflects the full extent of the delay?
  Response: High confidence that mitigation plans will work through integration issues by the end of the year, as reflected in guidance.

• Question from Patrick Wood (UBS): Is there anything that would preclude four percent plus as a reasonable midterm benchmark?
  Response: No major factors missing; the revised revenue guidance reduction is solely due to interventional integration issues.

• Question from Mike Sarconon (Jefferies): Can you elaborate on the guide for vascular and surgical versus interventional?
  Response: The guidance reduction is due to interventional. The low end of the revenue range assumes no growth in interventional for the remainder of the year, with vascular and surgical expected to continue solid performance but face tougher comps.

• Question from Mike Sarconon (Jefferies): Have you seen any impact from ACA subsidy expiration on patient demand and utilization?
  Response: No impact has been seen.

• Question from Jason Bednar (Piper Sandler): Can you comment on the Salesforce integration piece and confidence around resolving it?
  Response: Confident with current reps and training; ramp-up will take time (typically ~6 months) as hiring and training plans are in place.

• Question from Nathan Trey (Wells Fargo): How does the CMS rule change impact FreeZolve pricing?
  Response: The rule removes a shortcut pathway, but FreeZolve has other scenarios to demonstrate superiority; the clinical trial results will determine the opportunity.

• Question from Nathan Trey (Wells Fargo): What percentage of the DES market is Orsairo, and can you change its trajectory?
  Response: DES market is approximately flat; Orsairo has low share but has strong data and opportunity to outperform the market with more commercial bandwidth.

• Question from Mike Mattson (Needham & Company): What is the market opportunity and timing for EasyPlaz launch?
  Response: EasyPlaz is the first freeze-dried plasma licensed by the FDA; immediate priority is government/military market in the U.S. with revenue expected to be immaterial in 2026 and a contributor in 2027. The total market opportunity is under reassessment.

• Question from Mike Mattson (Needham & Company): What's at stake with the BioMag 2 trial for FreeZolve sales outside the U.S.?
  Response: Positive randomized trial data (expected late 2027) will address the data question, but guideline updates from ESC are also needed before broader sales ramp outside the U.S.

• Question from Anthony Patron (Mizuho Financial Group): What is Teleflex's view on U.S. procedure volumes for the back end of the year?
  Response: Procedure volume impact is not driving performance; no significant impact has been seen in businesses.

• Question from Anthony Patron (Mizuho Financial Group): Thoughts on capital allocation between share repurchases and debt service, and on future M&A.
  Response: Committed to $1 billion share repurchase and $800 million debt reduction. Focus is on executing current divestitures and integration; any future M&A would be tuck-in, not transformational.

• Question from Ravi Misra (Truist Securities): What's going on in the DCB ISR space, and can you comment on vascular ordering patterns?
  Response: DCB is a growth segment; evaluating options to get Lux platform into the U.S. and Japan. Vascular segment growth was strong despite some distributor inventory creep, expected to normalize; market is mid-single-digit growth.

• Question from Jason Bednar (Piper Sandler): Is the Biotronic integration issue with legacy Teleflex or Biotronic, and is there a geographic focus?
  Response: The integration struggles were disproportionately impacted by the Biotronic VI acquisition, with issues noted in the interventional business.

• Question from Travis (Bank of America): Talk about your philosophy on shareholder value creation.
  Response: Focused on learning the business, executing divestitures/integration, and developing a strategic approach. Committed to current capital return programs, innovation, and will provide more details on capital allocation after full assessment.

Contradiction Point 1

Nature and Duration of Interventional Integration Delays

Conflicting statements on whether delays are due to sales force integration or broader restructuring.

Mike Sarconon (Jefferies) - Mike Sarconon (Jefferies)

2026Q2: The guide reduction is entirely due to interventional. The low end of the revenue range (3.5-4.5%) assumes no growth in interventional for H2 (Q2 levels). - Jason Wideman(CEO)

Could you provide details on the guidance for vascular and surgical expectations in H2 compared to the interventional outlook? - Mike Polark (Wolfe Research)

2026Q1: The below-target growth in interventional in Q1 was expected due to two factors: the major restructuring related to the Vascular Intervention acquisition taking place and the sales force integration disruption. - John Deren(CFO)

Contradiction Point 2

Timeline for Freesolve (BioMag 2) Trial Readout

Inconsistency regarding when key clinical trial data will be available.

Mike Mattson (Needham & Company) - Mike Mattson (Needham & Company)

2026Q2: The BioMag 2 trial (2,000 patients vs. DES) will provide randomized data next year. - Jason Wideman(CEO)

What is at stake in FreeSolve's BioMag 2 trial, and could a positive result enable international sales growth? - Ravi Misra (Truist Securities)

2026Q1: The BIOMAG-II European pivotal trial for Freesolve... A data readout is expected in late 2027. - Lawrence Keusch(EVP, R&D)

Contradiction Point 3

Biotronic Integration Timeline and Status

Contradiction on the integration's progress and completion timeline.

Jason Bednar (Piper Sandler) - Jason Bednar (Piper Sandler)

2026Q2: Confidence is high that integration issues will be worked through by year-end... Salesforce ramp-up will take time (~6 months). - Jason Wideman(CEO)

Is the Biotronic integration delay fully captured in the timeline, and could you elaborate on the confidence in the Salesforce integration? - Michael Polark (Wolf Research)

20260226-2025 Q4: The Biotronic integration is going well, with sales force integration completed in the second half of 2025 and early 2026. - Stuart Randle(Interim CEO)

Contradiction Point 4

Impact of ACA Subsidy Expiration on U.S. Procedure Volumes

Contradiction on whether the expiration of ACA subsidies is impacting business volumes.

Patrick Wood (UBS) - Patrick Wood (UBS)

2026Q2: **No impact has been seen from ACA subsidy expiration.** - Jason Wideman(CEO)

"Are there factors, such as revised guidance or ACA subsidy expiration, that could hinder ~4% midterm growth or affect patient demand/utilization?" - Jayson Bedford (Raymond James)

20260226-2025 Q4: In Surgical, growth is driven by strength in the instrument portfolio... partially offset by the impact of volume-based procurement (VBP) in China. - Stuart Randle(Interim CEO), Lawrence Keusch(VP, Investor Relations)

Contradiction Point 5

BIOTRONIK (VI) Business Integration and Performance

Contradiction on the integration progress and reported growth of the VI business.

Jason Bedford (Raymond James and Associates) - Jason Bedford (Raymond James and Associates)

2026Q2: Confident in the transformational strategy; no major issues seen in first two months. Comprehensive assessment ongoing to shape long-term plan. VI integration issues are transient, not product-related. Main challenges are order-to-cash transitions, distributor transitions, and sales force (Salesforce) transitions. - Jason Wideman(CEO)

Can you discuss any aspects of the strategy that make you uncomfortable, areas of opportunity that were initially unclear, and the challenges with VI integration? - Michael Matson (Needham & Company, LLC)

2025Q3: BIOTRONIK (the VI business) grew nearly 7% in the quarter, which is encouraging. Details on the mix of PCI vs. peripheral focus within the VI business will be provided at the upcoming investor meeting. - Liam Kelly(CEO)